1318 related articles for article (PubMed ID: 32404196)
1. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
Li X; Song Y
J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
[TBL] [Abstract][Full Text] [Related]
2. Proteolysis targeting chimeras (PROTACs) in cancer therapy.
OcaƱa A; Pandiella A
J Exp Clin Cancer Res; 2020 Sep; 39(1):189. PubMed ID: 32933565
[TBL] [Abstract][Full Text] [Related]
3. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Studies of PROTACs in Hematological Malignancies.
Fuchs O; Bokorova R
Cardiovasc Hematol Disord Drug Targets; 2021; 21(1):7-22. PubMed ID: 33687890
[TBL] [Abstract][Full Text] [Related]
5. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule PROTACs: novel agents for cancer therapy.
Wan Y; Yan C; Gao H; Liu T
Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
An S; Fu L
EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
[TBL] [Abstract][Full Text] [Related]
8. Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?
Lospinoso Severini L; Bufalieri F; Infante P; Di Marcotullio L
Front Cell Dev Biol; 2022; 10():854352. PubMed ID: 35242765
[TBL] [Abstract][Full Text] [Related]
9. PROTAC-DB: an online database of PROTACs.
Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
[TBL] [Abstract][Full Text] [Related]
10. PROTAC: A promising technology for cancer treatment.
Zhou X; Dong R; Zhang JY; Zheng X; Sun LP
Eur J Med Chem; 2020 Oct; 203():112539. PubMed ID: 32698111
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in PROTACs for Drug Targeted Protein Research.
Yao T; Xiao H; Wang H; Xu X
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142231
[TBL] [Abstract][Full Text] [Related]
12. PROTACs technology for targeting non-oncoproteins: Advances and perspectives.
Wang C; Zhang Y; Xing D; Zhang R
Bioorg Chem; 2021 Sep; 114():105109. PubMed ID: 34175722
[TBL] [Abstract][Full Text] [Related]
13. New strategy for renal fibrosis: Targeting Smad3 proteins for ubiquitination and degradation.
Wang X; Feng S; Fan J; Li X; Wen Q; Luo N
Biochem Pharmacol; 2016 Sep; 116():200-9. PubMed ID: 27473774
[TBL] [Abstract][Full Text] [Related]
14. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges.
Zeng S; Huang W; Zheng X; Liyan Cheng ; Zhang Z; Wang J; Shen Z
Eur J Med Chem; 2021 Jan; 210():112981. PubMed ID: 33160761
[TBL] [Abstract][Full Text] [Related]
15. PROTACs in gastrointestinal cancers.
Chen Y; Yang Q; Xu J; Tang L; Zhang Y; Du F; Zhao Y; Wu X; Li M; Shen J; Ding R; Cao H; Li W; Li X; Chen M; Wu Z; Cho CH; Du Y; Wen Q; Xiao Z
Mol Ther Oncolytics; 2022 Dec; 27():204-223. PubMed ID: 36420306
[TBL] [Abstract][Full Text] [Related]
16. Bifunctional Peptide Nanofibrils for Targeted Protein Degradation.
Lin Z; Garcia BA; Lv D
Angew Chem Int Ed Engl; 2024 Jan; 63(3):e202316581. PubMed ID: 38059785
[TBL] [Abstract][Full Text] [Related]
17. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in Small Molecule PROTACs for the Treatment of Cancer.
Li W; Elhassan RM; Hou X; Fang H
Curr Med Chem; 2021; 28(24):4893-4909. PubMed ID: 33208057
[TBL] [Abstract][Full Text] [Related]
19. Targeted protein degradation by PROTACs.
Neklesa TK; Winkler JD; Crews CM
Pharmacol Ther; 2017 Jun; 174():138-144. PubMed ID: 28223226
[TBL] [Abstract][Full Text] [Related]
20. Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer.
Barghout SH
Anticancer Agents Med Chem; 2021; 21(2):214-230. PubMed ID: 32275492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]